Research Abstract
Our laboratory is engaged in the development of radiolabeled proteins and small molecules for multiple applications including cancer imaging and therapy and F-18-labeled small molecules for myocardial perfusion imaging. The focus of the cancer program is on the development of Cu-64- and Zr-89-labeled antibodies that can be used to noninvasively evaluate disease status as well as target status for therapy with the unlabeled antibody. We are also developing antibodies labeled with therapeutic radionuclides such as Lu-177 than can be used to treat small metastatic lesions before than develop become problemmatic.
